This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

This study has been completed.
Information provided by (Responsible Party):
Trevena Inc. Identifier:
First received: September 19, 2011
Last updated: August 24, 2012
Last verified: August 2012
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TRV120027 in subjects with heart failure and mild to moderate renal dysfunction.

Condition Intervention Phase
Heart Failure Kidney Disease Drug: TRV120027 Drug: Normal Saline Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Participant)
Official Title: A Randomized, Single-Blind, Placebo-Controlled, Adaptive, Ascending Dose Study to Evaluate the Effects of TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Mild to Moderate Renal Dysfunction

Resource links provided by NLM:

Further study details as provided by Trevena Inc.:

Primary Outcome Measures:
  • Change from Baseline Glomerular Filtration Rate [ Time Frame: Every hour during final 6 hours of study drug infusion ]
    Assessments of glomerular filtration rate are made hourly during the 6-hour study drug infusion on study Day 1 and study Day 3. GFR in hours 4-6 are compared to GFR in hours 1-3, and comparisons made between Placebo and TRV120027.

  • Change from Baseline in Vital Signs (Blood pressure, heart rate) [ Time Frame: Baseline, during infusion, and following infusion, on Study Day 1 and Study Day 3 ]
    Vital signs measurements made during and following drug infusion will be evaluated as a change from baseline, and comparing placebo to TRV120027. Assessments are made on study Day 1 and study Day 3.

Enrollment: 17
Study Start Date: August 2011
Study Completion Date: June 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TRV120027
TRV120027 administered as an IV infusion
Drug: TRV120027
IV infusion
Placebo Comparator: Normal Saline
Normal Saline administered as an IV infusion
Drug: Normal Saline
IV infusion


Ages Eligible for Study:   18 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written Informed Consent
  • Heart Failure
  • Mild to moderate renal dysfunction
  • Age 18- <75
  • Males and females (non-childbearing potential)

Exclusion Criteria:

  • Any significant disease or condition that would interfere with the interpretation of safety or efficacy or efficacy data as determined by the Investigator based on medical history, physical examination or laboratory tests
  • Any other serious life threatening disease that may impair the interpretation of safety or efficacy data from the study as determined by the Investigator
  • Allergy or clinically-significant intolerance to ARBs or ACE inhibitors
  • Clinical signs or symptoms of acute decompensated heart failure
  • Pregnant or lactating
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01444872

United States, Florida
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
United States, Minnesota
DaVita Clinical Research
Minneapolis, Minnesota, United States, 55404
United States, North Carolina
Duke Clinical Research Unit
Durham, North Carolina, United States, 27705
United States, Tennessee
New Orleans Center for Clinical Research
Knoxville, Tennessee, United States, 37920
Sponsors and Collaborators
Trevena Inc.
  More Information

Additional Information:
Responsible Party: Trevena Inc. Identifier: NCT01444872     History of Changes
Other Study ID Numbers: CP120027.1002
Study First Received: September 19, 2011
Last Updated: August 24, 2012

Additional relevant MeSH terms:
Heart Failure
Kidney Diseases
Renal Insufficiency
Heart Diseases
Cardiovascular Diseases
Urologic Diseases processed this record on June 23, 2017